Biopsy Guidance System Market Size, Share & Trends Report

Biopsy Guidance System Market Size, Share & Trends Analysis Report By Product (Stereotactic Guided Biopsy, MRI Guided Biopsy), By Application, By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Jul, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-4-68039-395-9
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 90

Report Overview 

The global biopsy guidance system market size was valued at USD 934.4 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.2% from 2021 to 2028. The demand for biopsy guidance systems is rapidly growing, owing to an upsurge in the prevalence of cancer cases across the globe, a surge in the geriatric population, an increasing preference for non-invasive procedures, technological advancements, and increasing government initiatives.

U.S. biopsy guidance system market size, by product, 2016 - 2028 (USD Million)

The COVID-19 pandemic has resulted in significant reductions in cancer screening, cancer management visits, and cancer procedures across the globe. The repercussions of delayed cancer detection owing to COVID-19 were investigated in a study undertaken in the U.K. and published in The Lancet Oncology in March 2021. The study covered data from over 100,000 people with breast, colorectal, esophageal, or lung cancer. The study found that 1 and 5-year cancer survival rates will be severely reduced as a result of the outbreak of COVID-19, owing to the lack of availability of screening services. As a result, owing to lockdowns, screening services have disrupted to some extent which may restrain the market growth over the forecast period.

The increasing prevalence of cancer is one of the key factors expected to boost the market during the forecast period. The increasing cases of cancer are majorly contributed due to the high adoption of sedentary lifestyles such as smoking, alcohol use, lack of exercise, poor nutrition, and obesity, across the globe. As a consequence, a high number of cancer cases are reported globally. For instance, according to the report published by the International Agency for Research on Cancer (IARC) in 2020, around 19.3 million cancer cases and 10.00 million cancer deaths were reported globally. As per the WHO statistics, the most common cancers in 2020 were:

  • Breast - 2.26 million

  • Lung - 2.21 million

  • Colon and rectum - 1.93 million

  • Prostate - 1.41 million

  • Skin (non-melanoma) - 1.20 million

  • Stomach - 1.09 million

The rising prevalence of cancer is thus boosting the development of more effective, safe, and advanced biopsy procedures, thereby leading to market growth. Increasing preference for non-invasive procedures is also a key factor contributing to market growth. The high costs of invasive biopsies, coupled with painful side effects, cause patients to postpone or avoid the treatment, resulting in a lack of diagnosis or diagnosis at a later stage of the disease. As a result, mortality rates are increasing, and treatments are becoming more complicated and expensive. Therefore, considering all these factors, the demand for non-invasive procedures is increasing, thereby, propelling the demand for biopsy guidance systems. Patients heal faster and are less traumatized as a result of these treatments. Furthermore, noninvasive biopsies are less expensive than traditional open surgical biopsies. Thereby, owing to the numerous benefits offered by minimally/non-invasive surgical technologies, the biopsy guidance systems market is expected to grow at a rapid pace over the forecast period.

New non-invasive technologies, known as smart biopsies, that enable real-time cancer tissue identification have been invented and are now being utilized in some hospitals to expedite cancer detection. Scaling up these projects from the lab to hospitals will make diagnosing cancer faster and cheaper, ensuing in patients getting access to early diagnosis. For instance:

  • University College London Hospitals developed a novel software, SmartTarget, to enhance prostate cancer diagnosis. SmartTarget Ltd. has commercialized this software, which is now in use in hospitals in the U.K. and the US.

  • SOLUS, an innovative tool is developed for the diagnosis of breast cancer. This device employs ultrasound and diffuse optics, an imaging method primarily used to assess tissue hemodynamics.

  • Dune Medical Devices also developed a device called SmartGuide based on radio frequency technology that might examine human tissue using electrical sensors in real-time throughout biopsy procedures.

Thus, the development of such smart biopsies will further create lucrative opportunities for key players, leading to market growth.

The increasing government and non-government initiatives related to the biopsy guidance system are also anticipated to boost market growth over the forecast period. Numerous government and private organizations, market-based enterprises, and hospitals are working on innovative programs to raise public awareness of cancer and the health benefits of early detection through screening services.

  • In India, the Rashtriya Arogya Nidhi initiative, run by the Ministry of Health & Family Welfare (MoHF&W), provides financial help to below poverty line (BPL) patients in the form of a one-time award of up to Rs 1,00,000 for treatment at super specialty hospitals/institutes or other government institutions.

  • The State Illness Assistance Fund (SIAF), in India, enables BPL people to get treatment for cancer or other life-threatening diseases at government hospitals for up to Rs 1,50,000.

  • In Australia, BreastScreen Australia Program seeks to reduce breast cancer-related morbidity and mortality by diagnosing the early diagnosis. Through this initiative, every 2 years, women aged 50 to 74 are offered to have a free screening mammogram.

  • The National Cancer Research Institute (NCRI), cancer research funding for breast cancer was USD 574.9 million, colorectal cancer was USD 256 million and lung cancer was USD 350.1 million amongst others in 2018.

Therefore, the growing number of government activities aimed at supporting research, raising awareness, and implementing mass screening programs for cancer are likely to drive the market.

The rising elderly population is considered one of the most significant risk factors for the development of cancer. For instance, according to the World Health Organization (WHO), the global population aged 60 years and above is projected to total 2 billion. The US Census Bureau also states that the number of adults aged 85 years and older is likely to surge from 6.4 million in 2016 to 19 million by 2060. In the elderly, cancer is one of the predominant causes of mortality and morbidity, and its incidence increases with aging. For instance, according to the National Cancer Institute, the incidence rate of cancer upsurged from 25 cases per 100,000 people below age 20 years to around 350 per 100,000 people amongst aged 45 to 49 years. Furthermore, it is higher than 1,000 per 100,000 persons in the 60+ age range.

Moreover, as per the most recent statistics from NCI’s Surveillance, Epidemiology, and End Results (SEER) Program, the average age of diagnosis for cancer is 66 years. Another research article published in NCBI, states that patients aged 65 and above account for more than 70% of cancer deaths across the globe. As a result of the rising elderly population, the use of biopsy guidance systems is likely to increase in the near term. Therefore, the rise in the geriatric population and their vulnerability to cancer is ultimately boosting the market growth over the forecast period.

Product Insights

The stereotactic guided biopsy segment held the largest revenue share of 39.7% in 2020 and is expected to witness a considerable growth rate over the forecast period. The stereotactic guided biopsy is advantageous as it is less invasive, provides rapid recovery time, and causes minimal scarring. Another advantage of this guidance technique in estimating tiny masses that are not visible in ultrasound. Moreover, it is an economical procedure as compared to open surgical biopsies. Thereby, the aforementioned advantages lead to a surge in demand for stereotactic guided biopsies. Moreover, the introduction of automated core-biopsy guns has accelerated the preference for this technique. Several healthcare centers have prolonged the potential use of stereotactic guided biopsy to nearly all complicated mammographic lesions.

The ultrasound-guided biopsy segment is anticipated to witness the fastest growth rate over the forecast period. It is the most effective imaging tool for guiding percutaneous biopsies and fine-needle aspirations. It is a safe and precise way for guiding needles into abdominal and pelvic organs and masses utilizing real-time imaging. It has several benefits over computed tomography-guided biopsies, including portability, cost, and the absence of ionizing radiation. Biopsies of lesions as tiny as 1 cm can be conducted if the operation is safe and the mass can be seen sonographically. Thus, owing to the above-mentioned benefits, ultrasound-guided breast biopsy gaining popularity amongst patients.

Application Insights

The brain biopsy segment dominated the market and held the largest revenue share of 42.8% in 2020 and is anticipated to witness a considerable growth rate over the forecast period. The increased incidence of brain cancer is the key major factor driving the demand for brain biopsies. For instance, according to the National Brain Tumor Society, a projected 700,000 people in the US are living with a primary brain tumor, and nearly 85,000 more will be diagnosed in 2021. Moreover, the increasing geriatric population is also driving the growth of the brain biopsy segment. The average age at diagnosis for a primary brain tumor is 60 years. An estimated 69,950 adults age 40+ are expected to be diagnosed with a primary brain tumor in 2021 in the US. In addition, developments in biopsy guidance systems such as open Magnetic Resonance Image (MRI) guided robotic systems for brain biopsy, will add to segment growth.

The breast biopsy segment is anticipated to witness the fastest growth rate over the forecast period. The rising prevalence of breast cancer among women after menopause, and technological advancement are the key factor fueling the segment growth. For instance, according to Breastcancer.org. around 281,550 new cases of invasive breast cancer and 49,290 new cases of non-invasive breast cancer were reported in 2020 in the U.S. Also, as per the WHO, in 2020, around 2.3 million women were diagnosed with breast cancer, and around 685 000 deaths were reported globally. Thus, the high prevalence of breast cancer and growing demand for advanced minimally invasive therapies are leading to segment growth.

End-use Insights

The hospitals segment dominated the market and held the largest revenue share of 36.1% in 2020 and is expected to witness a significant growth rate over the forecast period. The segment's dominance can be attributed to the increase in the use of biopsy guidance systems in hospitals across the globe. Patients are increasingly opting for minimally invasive surgical procedures to avoid traditional surgical complexities and side effects, boosting sales of biopsy guidance systems and propelling segment growth. Moreover, the increasing number of populations suffering from cancer is the key factor boosting the hospital segment growth. For instance, according to the American Cancer Society, around 60,530 new cases of leukemia and 23,100 deaths from leukemia were reported in the U.S. in 2020. Furthermore, the growing geriatric population, which is among the vast patient pool admitted to hospitals for early cancer diagnosis, might fuel the segment growth.

Global biopsy guidance system market share, by end-use, 2020 (%) 

The specialty clinics segment is expected to witness the fastest growth over the forecast period. The rise in popularity of out-of-hospital, single-specialty healthcare centers in recent years has provided the considerable potential for both new and established healthcare enterprises. Growing consumer awareness concerning the accessibility of diagnostic and screening procedures for chronic diseases in such clinics is propelling the demand for technologies such as stereotactic-guided biopsies. Furthermore, the capacity of specialty clinics to provide a tailored solution for a specific purpose, combined with specialized infrastructure, is fueling the segment's growth.

Regional Insights

North America dominated the biopsy guidance systems market and accounted for the largest revenue share of 45.4% in 2020 and is expected to witness a considerable growth rate of 5.3% over the forecast period. North America accounted for the majority share due to continuous expansion in cancer diagnostic companies and the growing demand for innovative treatments. Government agencies, non-profit healthcare organizations, pharmaceutical, and biotech companies, and research institutes are investing substantially in medical and health-related research and development, which is also anticipated to fuel market growth.

In Asia Pacific, the market is anticipated to exhibit lucrative growth during the forecast period. Traditional biopsy techniques, such as core-needle biopsies and surgical biopsies, still dominate the cancer diagnostic market in Asian countries. A significant increase in the incidence of cancer is a key factor responsible for regional market growth. For instance, as per the American Cancer Society, Inc., in 2018, around 8.2 million cases of cancer and 5.2 million deaths were reported in Southern, Eastern, and South-Eastern Asia, conforming to about half of the cancer burden globally. A recent report published by National Cancer Registry Programme (NCRP) estimated that the number of cancer cases in India is projected to surge from 13.9 lakh in 2020 to 15.7 lakh by 2025. As a result of the rising number of cancer cases and advancements in biopsy guidance systems, the market is anticipated to expand over the forecast period.

Key Companies & Market Share Insights

Key players are involved in adopting strategies such as mergers and acquisitions, partnerships, and launching new products to strengthen their foothold in the market.

  • In February 2020, NeoDynamics AB is planning to launch the new pulse biopsy system ‘NeoNavia’, for breast cancer diagnosis.

  • In April 2019, Hologic Inc. launched the Trident H.D. specimen radiography system in the US. It helps provide higher image quality as well as a protocol for verification of sample during breast-conserving procedures and stereotactic breast biopsies. It also assists physicians in obtaining superior breast surgery specimens as well as a variety of clinical and biopsy samples. This introduction broadened the firm's product portfolio.

  • In June 2019, Volpara Health Technologies entered a legal agreement to purchase MRS Systems Inc. (MRS) in the US. The agreement aided Volpara to expand its product line and use its synthetic intelligence (A.I.) and system acquisition (ML) expertise to advance customized breast care.

Some of the prominent players in the biopsy guidance system market include:

  • Becton, Dickinson, and Company

  • Hologic, Inc.

  • Devicor Medical Products, Inc.

  • B. Braun Melsungen AG

  • ARGON MEDICAL

  • Boston Scientific Corporation

  • INRAD Inc.

  • Cook Medical

  • PLANMED OY

Biopsy Guidance System Market Report Scope

Report Attribute

Details

Market size value in 2021

USD 969.6 million

Revenue forecast in 2028

USD 1,383.5 million

Growth Rate

CAGR of 5.2% from 2021 to 2028

Base year for estimation

2020

Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa (MEA)

Country scope

U.S.; Canada; U.K.; Germany; Japan; China; Brazil; Mexico; South Africa; Saudi Arabia

Key companies profiled

Becton, Dickinson and Company; Hologic, Inc.; Devicor Medical Products, Inc.; B. Braun Melsungen AG; ARGON MEDICAL; Boston Scientific Corporation; INRAD Inc.; Cook Medical; PLANMED OY

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global biopsy guidance system market report on the basis of product, application, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2016 - 2028)

    • Stereotactic Guided Biopsy

    • Ultrasound Guided Biopsy

    • MRI Guided Biopsy

  • Application Outlook (Revenue, USD Million, 2016 - 2028)

    • Brain Biopsy

    • Breast Biopsy

    • Other Applications

  • End-use Outlook (Revenue, USD Million, 2016 - 2028)

    • Hospitals

    • Specialty Clinics

    • Diagnostic Centers

    • Research and Academic Institutes

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.